Launching and Funding Startups with the Chinese University of Hong Kong

By Joey Wong, Investor Research Analyst, Hong Kong BD, LSN

Life Science Nation (LSN) is collaborating with the Pre-Incubation (PI) Centre at the Chinese University of Hong Kong (CUHK) to deliver an educational workshop on August 23- 24, from 7:00 – 9:00 AM EDT. With a decade of expertise in helping early-stage life science companies fundraise and build strategic relationships, LSN has developed a curriculum delivering several master class workshops to global tech hubs and incubators. Conducted virtually over two days, the workshop will be led by Dennis Ford, CEO of Life Science Nation, and LSN staff members who are experienced in Asia business development. The workshop is catered to new founders and entrepreneurs of early-stage, seed to series B life science companies to navigate their way in launching or progressing their businesses, and covers a wide range of fundamental entrepreneurial concepts:

  • How to launch a startup entity and perform entrepreneurial due diligence
  • Branding and messaging
  • The importance of telling a cogent company story through multiple modalities
  • Ten myths of fundraising

LSN is honored to work with the CUHK PI Centre and their constituents for the first time. The PI Centre is a university-wide initiative at CUHK that stimulates creativity and entrepreneurship, supporting aspiring entrepreneurs to prepare and fine-tune their startups since 2014. The center will host a gathering to facilitate the delivery of the workshop. We look forward to meeting the entrepreneurs at CUHK and providing a constructive experience to advance the success of their businesses.

20220803_LSN_poster_1920x1080_F

Sign up or find more information about the workshop here. Contact Joey Wong, Research Analyst, Hong Kong Business Development at j.wong@lifesciencenation.com with questions

LSN is open to collaborating with tech hubs and incubators around the globe. Find out more about LSN’s education programs here.

RESI-Boston-2022-Banner - new - 1100px

Hot Investor Mandate: USA-Based VC Firm Invests in Life Science Companies From Seed to Series B Rounds, With Strong Interest in AI-Based Technologies

A venture capital firm based in the USA invests in companies in Consumer, Crypto and Life Sciences & Digital Health. For companies in the life sciences, the firm generally invests in Seed and Series A/B rounds, committing between $1-10M in capital.

Within the life sciences, the firm is willing to invest in therapeutics, diagnostics, MedTech, digital health, and R&D services. For therapeutics, the firm will consider therapeutics that are first-in-class, either a novel target or novel therapeutic, but is agnostic to indication. For diagnostics, MedTech, Digital Health, and R&D services, the firm focuses on AI-based technologies. Previous investments include AI-based drug discovery platforms, pathology screening, diagnostic services, and care management platforms.

The firm looks for companies with a strong management team, large market opportunities, and disruptive technology. When investing, the firm is willing to lead or co-invest, and will occasionally take a board seat after investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: VC Firm With Offices in North America & Asia Invests in Therapeutics, Diagnostics, and Digital Health in Relation to Cell Therapy and Regenerative Medicine

An early stage venture capital firm is dedicated to building next generation companies in the healthcare sector. The fund is focused on the cell therapy and regenerative medicine sector and will consider opportunities encompassing therapeutics, diagnostics, and those harnessing data to revolutionize the sector. The firm partners with passionate teams that are backed by strong scientific platforms and will primarily invest in preclinical stage assets, contributing $1 – 2M initially. With operations in North America and Asia, the fund take a global approach to building value in their portfolio by linking these two important life science markets and leveraging the respective advantages of each ecosystem.

The firm invests exclusively in technologies relating to cell therapy and regenerative medicine, including precision medicine tools and discovery of new treatment modalities. The company can be in therapeutics, diagnostics or digital health. The firm’s primary areas of interest are oncology, autoimmune disorders, CNS, cardiovascular, renal and liver.

Most of the firm’s investments are in companies either located or looking to enter the Japanese market. The firm can lead or co-invest, and will generally take a board seat when leading.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Corporate VC Arm of Conglomerate Invests in Series A to B Rounds in Therapeutics, Diagnostics, and Digital Health, With Interest in Large Market Opportunities

A corporate venture arm under a large conglomerate invests in a wide range of industries including biotech, ICT, media, food, among others. With regards to life sciences and healthcare, The firm generally invests in Series A to B rounds but has participated in as early as pre-Series A. Typical initial size of investment is over $1M, and is subject to larger amounts depending on the stage of the company. The firm has invested mostly in USA and Korea, but is open to considering global opportunities.

The firm will consider opportunities across therapeutics, diagnostics, digital health. Within these sectors, the firm is most interested in drug discovery and development, diagnostics, digital health, and microbiome. In therapeutics, the firm is open to both pre-clinical and clinical assets & platforms and will consider all different types of modalities (small molecule, antibodies, cell/gene therapy). The firm will consider all indications but is interested in large markets including oncology/immuno-oncology and CNS.

The firm has no specific management team requirements. The firm can act as either a lead or co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Investment Fund of Large Holding Company Seeks Opportunities in Diagnostics and Digital Health Across the Globe

A venture capital fund of a large holding company looks to provide a unique stepping stone for successful companies to broaden their global reach. The firm offers partners deep understanding of relevant audiences and a unique opportunity for truly innovative, trail-blazing consumer-related digital health ventures. The firm is looking to invest in digital therapeutics, POC diagnostics, and other dHealth companies from seed stage and beyond. The firm is interested in companies with well defined, relevant products and solutions, preferably with initial validation or proof-of-concept. The firm invests globally.

Within the digital health and POC diagnostics space, the firm has many areas of interest. These include, but are not limited to, telemedicine, remote monitoring, patient adherence, FemTech and aging, medication dispensing, digital therapeutics, POC and home diagnostics.

The firm has no specific requirements for company and management team, and makes decisions on a case-by-case basis. The firm can lead or co-invest.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Branding & Messaging Simplified

By Karen Deyo, Director of Investor Research, Israel BD, LSN

Last week, Greg Mannix and I hosted a workshop titled Branding and Messaging from Seed to Series B, aimed at helping startups know the value of marketing collateral, what to use, and how to use it. Creating good marketing collateral is a long and evolving process – you are never done; you constantly update and improve it as time goes on and your company develops. New milestones replace old and new evidence takes center stage, and as you gain more expertise, your story matures.

One key takeaway from the workshop is that you need to have the whole package of marketing collateral, and that the story should be consistent throughout. This means having a tagline, an elevator pitch, an executive summary, a one-page tear sheet and a pitch deck crafted from the same main message, condensed to varying lengths. Furthermore, this story should give investors the whole picture, covering the three main pillars:

  • Your technology (what is it, what makes it unique, what problem are you solving and how are you improving over existing options)
  • Your market (what competitors are there, both on the market and still in development, what is the market size, including TAM, SAM, and SOM, how long to reach market and what is your path to entry)
  • Your business (regulatory/reimbursement, IP status, exit strategy, and management team).

Clearly, this is a lot of information, and not something you can cover in great depth in your marketing collateral. The goal in this is to give investors just enough to give them an accurate picture so that they can get more details in future meetings if they are a fit.

Another major piece is knowing your audience and tailoring your language accordingly. Does the person you are speaking to have a financial background, or a science-related PhD? You tailor your language accordingly – you don’t want to overload someone who may not be an expert in the field with overly technical scientific jargon. At the same time, if the person has a PhD in a related field, you don’t want to waste time oversimplifying and giving basic information that they already know. Finding a simple, concise description for your company can be difficult, but it serves as a great starting point – something everyone can understand without being too basic, and a great starting off point should you want to get into a more technical discussion. Ultimately, you, or a member of your team, should be able to cover both the science and the business in depth, as both will be needed in the stages of due diligence.

As I mentioned above, your marketing collateral will be constantly changing – you will hone it as you have more conversations and get more feedback. Take note of any frequently asked questions – these are areas you may want to expand upon in your marketing collateral if they come up often enough. A final note, especially to the earliest stage companies: investors understand that you will not have answers to all these questions – for some, you are simply too early. However, you are never too early to consider your options and possible approaches. Giving an investor a well thought out and reasoned answer for a possible solution in the future will go a long way to reassure them that you are the right person to partner with.

Life Science Nation is offering one final workshop, Keys to Successful Partnering on August 17 at 1 PM EDT. Sign up to join for free!

RESI-Boston-2022-Banner - new - 1100px

Partnering Platform Tutorials

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

claire

Partnering opens for RESI Boston Monday, August 29! The partnering platform opens early to give attendees the opportunity to fill out their company profiles and start booking meetings with investors based on several relevant criteria, including location, sector, indication, stage of development, and more. To help attendees best understand and utilize the powerful tools within the partnering platform, Life Science Nation is hosting two free partnering tutorials August 31 and September 6.

While the partnering platform is an exceptional tool designed to match potential partners for well-fitting meetings, it’s the founder, team, and technology that cross the finish line. Learning how to optimize partnering for success will help entrepreneurs stand out, save time, and make meaningful connections at RESI. We hope you’ll join us and learn how the right partnering platform can optimize your early-stage fundraising strategy.

Partnering

RESI-Boston-2022-Banner - new - 1100px